Publication: Wednesday, April 21, 2021 6:01 AM
Spain has already received the first batch of vaccines from Janssen and everything is ready to start the distribution of the Johnson & Johnson formula against the coronavirus from today among the autonomous communities. At the end of the evening on Tuesday, the Minister of Health, Carolina Darias, was present at the reception of the first 146,000 doses of Janssen, when she took the opportunity to celebrate the arrival of the fourth vaccine – as well as those of Pfizer, Moderna and AstraZeneca that our country will use to deal with the pandemic.
“We have just received 146,000 doses which will be distributed immediately so that the autonomous communities can start vaccinating them as soon as possible”, explained the head of the Health portfolio, stressing “the satisfaction of contributing with one more vaccine to continue inoculating all the citizenship of our country “; a new formula with which it pursues, as indicated,” the objective of the Spanish government, the autonomous communities and the cities: to vaccinate, to vaccinate and to vaccinate “.
This is how Darias spoke just hours after the European Medicines Agency (EMA) gave the green light for the use of the Janssen vaccine in European countries. Its distribution was paralyzed as the European body investigated the reason for eight cases of thrombosis recorded among seven million people who received the Johnson & Johnson formula in the United States. A situation similar to that which had also been experienced recently with the AstraZeneca vaccine.
In fact, although the EMA has approved to continue to vaccinate with Janssen, it recognized that same Tuesday a “possible link” in the use of these doses with “very rare cases” of infrequent thrombi with blood platelets. bass. Specifically, he reported that all cases recorded to date “have occurred in people under the age of 60 within three weeks of vaccination, the majority in women.” However, he clarified: “Based on the evidence currently available, the specific risk factors have not been confirmed.”
The EMA recommends adding “a risk warning in the product information”
Thus, he concluded that “the general benefits of Janssen outweigh the risks of side effects”, although he considers it necessary “to add a warning in the product information” about these unusual blood clots. , which should “be included as a very rare side effects of the vaccine”. On the recommendation of the European Medicines Agency and with the first batch of Janssen already in Spain, the doses of this vaccine are distributed as follows:
Madrid 20,900 doses Catalonia 24,000 doses Euskadi 6,850 doses Navarre 2,050 doses Andalusia 26,150 doses Galicia 8,500 doses Extremadura 3,000 doses Canary Islands 6,000 doses Cantabria 1,800 doses Castile and León 7,400 doses Asturias 3,100 doses La Rioja 1,000 doses Balearic Islands 3,600 doses
Who will it be for and how it works
The arrival of Janssen in Spain represents a new impetus in the vaccination campaign in our country, since it is a single-dose vaccine. In other words, only one dose is needed to immunize a person against the coronavirus, which could lead Spain to achieve the goals set by the government: to vaccinate 70% of the population in summer. Initially, as stated by Health, the Johnson & Johnson product will be aimed at people aged 70 to 79.
Jannsen’s vaccine is of the non-replicating viral vector type. It uses a human adenovirus which is modified so that it cannot replicate and so that it expresses in its membrane the spike (S) protein of the virus, which our body will recognize as foreign and against which it will create antibodies. In this way, it prevents it from replicating in the body and developing diseases. This vaccine is administered at a dose of 0.5 ml by intramuscular injection.
Clinical trials with Janssen have shown a 67% efficacy in the vaccine, so initially it does not have the same “strength” as Pfizer or Moderna. However, according to what is stated by the Interritorial Health Council, her ability to immunize is even greater in the 65-year-old group (reaching 82.4% of effectiveness) and in the over 75-year-old group (she has even reaches 100%). In this way, its total effectiveness could reach 76.7% at 28 days of vaccination against 14 days measured by the EMA.
According to data provided by Health, the most common adverse reactions recorded in patients inoculated with Janssen were muscle pain at the injection site (more than 40%), headache, fatigue and myalgia (approximately 30%). %), nausea (15%) and fever. . Recently, at laSexta, we heard from a volunteer in one of Janssen’s clinical trials who recounted how the process of participating in the research went, as well as the adverse effects he experienced within hours. following the injection of the dose.
Vaccination in Spain
Since the start of the vaccination process on December 27, 2020, and until today in Spain, 13,041,032 doses of AstraZeneca, Pfizer and Moderna vaccines have already been administered, as stated in a report from the Ministry of Health. This represents 87.4% of those distributed among the autonomous communities. In this sense, 9,588,913 people have received at least one dose of a vaccine (20.2% of the population) and 3,452,119 have already received the full treatment regimen (7.3% of the population).
If this data is broken down by vaccine, 9,010,682 doses of Pfizer vaccine were administered, 5.7 million people received the first dose and 3.2 million the full program. For its part, 809,370 doses of Moderna have already been inoculated in our country (more than 573,000 people have received a dose of this formula and 235,699 the complete regimen). For AstraZeneca, 3,220,980 doses have already been inoculated, although 3,220,784 people received one and 196 both. This second figure is remarkably low due to the discontinuation of the administration of this vaccine in Spain due to the registration, as happened with Janssen, of several cases of thrombi linked to the vaccine.